Baitha Palanggatan Maggadani

Baitha Palanggatan Maggadani

Auto-generated profile, based on publicly available information

Baitha Palanggatan Maggadani

Pharmaceutical-Medicinal Chemistry and Bioanalysis Laboratory Depok West Java 16424 University of Indonesia Faculty of Pharmacy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Indonesian Journal of Pharmacy
Verified
Journal Article
Open access
PDF file
HHHayun Hayun
Hayun Hayun
BMBaitha P Maggadani
Baitha P Maggadani
NANurul Amalina
Nurul Amalina
Determination of sibutramine adulterated in herbal slimming product using thin layer chromatography (TLC) densitometric method with TLC silica gel 60 F254 aluminium plate as stationary phase and mixture of toluen-diethylamine (10:0.3) as mobile phase has been developed. The calibration curve in the concentration range of 0.50 to 5.00 µg/spot showed good linier relationship (r2 = 0.9986). The limit of detection and quantitation (LOD and LOQ) were 217.5 ng and 724.9 ng/spot, respectively. The method gave satisfactory specificity, linierity, precision and accuracy validation criteria and was applied for determination of sibutramine in herbal slimming products obtained from several drugstrores in Depok City, West Java, Indonesia. Results of the determination showed that six of seven samples analyzed were detected containing sibutramine HCl with the concentration of 2.45 - 26.24 mg in a single dosage of slimming herbal products

7 July 2024 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
BMBaitha Palanggatan Maggadani
Baitha Palanggatan Maggadani
RRRisa Rahmayati
Risa Rahmayati
TRTaufiq Indra Rukmana
Taufiq Indra Rukmana
CMCallista Andinie Mulyadi
Callista Andinie Mulyadi
Objective: This study aimed to evaluate the stability of retinol in facial serum products under various storage conditions during a specific period after the product is opened. Retinol analysis will be conducted using reversed-phase high-performance liquid chromatography with a UV detector. Methods: The optimum analytical method in this study was validated according to the ICH Q2 (R1) guideline. The chromatographic separation of retinol was achieved on RP-HPLC isocratic elution method at a wavelength of 324 nm, C18 column, mobile phase of methanol-acetonitrile (90:10), and a flow rate of 0.8 ml/min. Results: The recovery value for this method was 98.06%-101.6,6%, with RSD ≤ 2%. Limit of Detection (LOD) and limit of Quantification (LOQ) values obtained were 1.1819 µg/ml and 3.9399 µg/ml. Determining retinol levels in face serum samples with variation in storage conditions was conducted on d 0, 7, 14, 21, and 30. The retinol levels in all storage conditions decreased over the 30 d, ranging from 25% to 79%. The highest decrease was observed in samples stored in transparent containers and exposed to light, with a reduction of 79% and an average weekly decrease of 17%. Conclusion: Stability evaluation of retinol in the serum formulation showed decreased retinol concentration over time during storage. Transferring the product to a secondary container and exposure to light resulted in a higher concentration decrease than storing it in the original bottle.

24 January 2026 in F1000Research
Verified
Journal Article
Open access
AWAngelique Valentia Wijaya
Angelique Valentia Wijaya
RSRani Sauriasari
Rani Sauriasari
BMBaitha Palanggatan Maggadani
Baitha Palanggatan Maggadani
DRDevo Fitrah Ramadhan
Devo Fitrah Ramadhan
MRMohd Salleh Rofiee
Mohd Salleh Rofiee
RJRichard Muhammad Johari James
Richard Muhammad Johari James
Background Diabetic Kidney Disease (DKD) is one of the microvascular complications of Type 2 Diabetes Mellitus (T2DM) which tended not to be detected early, necessitating more effective biomarkers for its detection. HbA1c showed a negative correlation with the estimated glomerular filtration rate (eGFR) and was significantly associated with an increased urine albumin-creatinine ratio (UACR), thereby influencing the progression of DKD. Objective This study was an untargeted metabolomics study and aimed to compare the urinary metabolites of low DKD risk T2DM patients with controlled and uncontrolled HbA1c in patients taking metformin-glimepiride. Materials and Methods This study conducted as a cross-sectional study using non-probability sampling at Pasar Minggu District Health Center, 32 samples were divided into controlled (n=16) and uncontrolled HbA1c groups (n=16). Blood samples were collected for HbA1c and eGFR measurements, while urine samples were analyzed for UACR and metabolites. Analysis was performed using LC/MS-QTOF and the data was processed using MetaboAnalyst 6.0 and various databases. The discrimination results of the two groups were visualized through Principal Component Analysis (PCA) and Partial Least Squares-Discriminant Analysis (PLS-DA). The significance of metabolites between groups was selected with the parameters VIP>1, log2(FC)>1.2, and p-value0.65): oxaloacetate and 5′-phosphoribosyl-N-formylglycinamidine, which decreased in the uncontrolled HbA1c group, and (S)-dihydroorotate, which increased in the uncontrolled HbA1c group. The involved metabolic pathways included (1) alanine, aspartate, and glutamate, (2) citric acid (Krebs cycle), (3) gluconeogenesis, (4) pyruvate, (5) pyrimidine, and (6) purine. Conclusion Based on these results, there’s a significant difference in urine metabolites of the two groups that potentially be the biomarkers for DKD progression with controlled and uncontrolled HbA1c.

30 June 2021 in medRxiv
Verified
Preprint
Open access
PDF file
BMBaitha Palanggatan Maggadani
Baitha Palanggatan Maggadani
KJKathleen Irena Junusmin
Kathleen Irena Junusmin
LSLevana L. Sani
Levana L. Sani
CMCaroline Mahendra
Caroline Mahendra
MAMargareta Amelia
Margareta Amelia
SHSamuel Haryono
Samuel Haryono
Tamoxifen is a Selective Estrogen-Receptor Modulator (SERM) commonly prescribed for standard of care in estrogen receptor positive (ER+) breast cancer as an adjuvant therapy. Tamoxifen is metabolized by CYP2D6 into its active metabolite, endoxifen, which has been known to play an important role in reducing risk of ER+ breast cancer recurrence. CYP2D6 is a highly polymorphic gene with more than 100 alleles. The phenotype of this gene is categorized into ultrarapid metabolizer (UM), normal metabolizer (NM), intermediate metabolizer (IM), and poor metabolizer (PM). Certain CYP2D6 polymorphisms may cause reduced activity of this enzyme. Studies have found that reduced CYP2D6 activity in IM and PM patients causes low efficacy of standard tamoxifen therapy. This study aims to observe the distribution of CYP2D6 alleles and its correlation with endoxifen levels in Indonesian ER+ breast cancer patients. 151 patients who have received tamoxifen therapy for at least eight weeks were recruited prospectively. DNA and blood samples were collected with buccal swab and finger-prick methods, respectively. Genotyping was performed using the qPCR method while metabolite level measurement was performed using high performance liquid chromatography tandem mass spectrometry. We found that 40.67% of ER+ breast cancer patients recruited were IM. CYP2D6*10 was the most abundant allele (0.288) in this population, and *10/*36 was the most frequently observed diplotype (0.236). Endoxifen levels between the NM-PM, NM-IM, and IM-PM were statistically significant ( p -value = 6.26 × 10 −5 , 9.12 × 10 −5 , and 4.714 × 10 −3 , respectively), and dose increase of tamoxifen to 40 mg daily successfully increased endoxifen levels in IMs to a similar level with NMs at baseline. Given these findings, implementing pharmacogenomic testing of CYP2D6 on ER+ breast cancer women who are about to undergo tamoxifen therapy may be beneficial to increase the likelihood of achieving expected endoxifen levels, thus better treatment efficacy.

10 September 2026 in F1000Research
Verified
Journal Article
Open access
PDF file
GGGabriella Gabriella
Gabriella Gabriella
RSRani Sauriasari
Rani Sauriasari
ADAulya Annisa Desiafitri
Aulya Annisa Desiafitri
PBPatricia Felia Budijarto
Patricia Felia Budijarto
SRShofiah Nur Rohmah
Shofiah Nur Rohmah
MRMohammad Salleh Rofiee
Mohammad Salleh Rofiee
Background Diabetic Kidney Disease (DKD) leads to albuminuria and gradually progresses to renal insufficiency. However, 20–40% of DKD cases are normoalbuminuric DKD, namely impaired kidney function with normal albumin levels, limiting the accuracy of albuminuria as an early biomarker. With metabolomic approach, this study aimed to understand the distinctions in disrupted urinary metabolic pathways between normoalbuminuric DKD (NA-DKD) and albuminuric DKD (A-DKD) patients. Methods A cross-sectional study with total of 16 NA-DKD and 16 A-DKD patients with no discernible differences in demographic or clinical characteristics from Pasar Minggu District Health Center and Jati Padang Regional Hospital in Jakarta were asked to provide midstream morning urine samples. All subjects were analyzed using untargeted metabolomic analysis with Quadruple Time of Flight Liquid Chromatography-Mass Spectrometry. Signature metabolites were determined by Projections to Latent Structures Discriminant Analysis (PLS-DA) with Variable Importance for the Projection (VIP) >1.0, fold change >1.2, p-value 0.65. Results The PLS-DA score plot demonstrated a clear separation between the NA-DKD and A-DKD groups, indicating distinct urinary metabolic profiles. Twenty urinary metabolites differed significantly between the two groups. Pathway analysis revealed alterations in glycerophospholipid, ether lipid, phenylalanine, and tryptophan metabolism. Receiver operating characteristic (ROC) analysis identified three metabolites–glycerophosphocholine, hippuric acid, and 2-aminobenzoic acid–with an area under curve (AUC) >0.65. These metabolites were significantly reduced in the A-DKD group, indicating their potential discriminatory performance. Conclusions Glycerophosphocholine, hippuric acid, and 2-aminobenzoic acid may serve as potential biomarkers for distinguishing albuminuric from normoalbuminuric DKD. These findings provide insight into metabolic alterations associated with DKD and warrant further validation in larger cohorts using targeted metabolomic approaches.

30 March 2026 in Indonesian Journal of Chemistry
Verified
Journal Article
Open access
PDF file
PAPedro Anugerah Aswan
Pedro Anugerah Aswan
BMBaitha Palanggatan Maggadani
Baitha Palanggatan Maggadani
WFWilzar Fachri
Wilzar Fachri
Raditya IswandanaRaditya Iswandana
Raditya Iswandana
The development of robust analytical methods is essential for quality control of nanoethosomal formulations containing asiaticoside and α-mangostin, bioactive compounds with anti-inflammatory and antioxidant properties. Simultaneous quantification within nanocarriers is challenging and requires validated techniques. This study established a precise HPLC method, in accordance with ICH Q2(R2) guidelines, for the concurrent determination of both compounds. The technique demonstrated excellent linearity (R2 > 0.999), precision (%RSD < 2%), and accuracy (95–105% recovery). The nanoethosomal system also achieved high encapsulation efficiencies of 94.76% for asiaticoside and 99.27% for α-mangostin. This validated method provides a reliable tool for standardizing these complex nano-formulations, supporting their further development and clinical translation.